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Schizophrenia is a serious mental disease with a high mortality rate and severe social con-
sequences. Due to insufficient knowledge about its etiopathogenesis, curative treatments 
are not available. One of the most promising new research concepts is the mild enceph-
alitis hypothesis of schizophrenia, developed mainly by Karl Bechter and Norbert Müller. 
According to this hypothesis, a significant subgroup of schizophrenia patients suffer from 
a mild, but chronic, form of encephalitis with markedly different etiologies ranging from 
viral infections, traumas to autoimmune diseases. This inflammatory process is thought to 
occur in the beginning or during the course of the disease. In this article, we investigate 
the consequences of the mild encephalitis hypothesis of schizophrenia for the scientific 
community, and evaluate these consequences ethically. The mild encephalitis hypothesis 
implies that schizophrenia would no longer be considered an incurable psychiatric disor-
der. Instead, it would be considered a chronic, but treatable, neurological disease. This 
paradigm shift would doubtlessly have significant consequences: (1) major reforms would 
be necessary in the theoretical conceptualization of schizophrenia, which would challenge 
the psychiatric diagnostic systems, Diagnostic and Statistical Manual of Mental Disorders 
version 5 and ICD-10. (2) Psychotic patients should be treated in interdisciplinary teams, 
optimally in neuropsychiatric units; additionally, specialists for endocrinology, diabetology, 
and cardiology should be consulted for the frequently occuring somatic comorbidities. (3) 
Current diagnostic procedures and (4) therapies would have to be modified significantly. 
(5) There might be repercussions for the pharmaceutical industry as well: first, because 
old drugs with expired patent protection could partly replace expensive drugs and, sec-
ond, because there would be a demand for the development of new anti-inflammatory 
drugs. (6) Legal evaluation of compulsory treatment orders might have to be reconsidered 
in light of causal therapies; leading to increased legal approval and reduced need for 
compulsory treatment orders due to better patient compliance. (7) The social inclusion of 
patients might improve, if treatment became more effective regarding cognitive and social 
functioning. (8) The stigmatization of patients and their relatives might decrease.
Keywords: schizophrenia, ethics, medical, mild encephalitis, stigmatization, compulsory treatment, autoimmune 
encephalitis
Abbreviations: COX-2, cyclooxygenase-2; CSF, cerebrospinal fluid; CT, computer tomography; DSM-5, Diagnostic and 
Statistical Manual of Mental Disorders version 5; FDG-PET, fluorodeoxyglucose positron emission tomography; NAC, 
N-acetylcysteine; NMDA, N-methyl-d-aspartate; NMDAR, N-methyl-d-aspartate receptor; MRI, magnetic resonance imag-
ing; PUFA, poly-unsaturated fatty acids; RDoC, Research Domain Criteria project.
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introdUCtion
Schizophrenia is a severe psychiatric disease that affects about 1% 
of the worldwide population. It is characterized by hallucinations, 
delusions, disorganization of thought and behavior, depression, 
flattened affect, cognitive disorders, and social withdrawal. In 
most cases, the disease takes a chronic, relapsing-remitting course 
with progressive cognitive decline and a significantly reduced life-
expectancy. Most patients are excluded from society because of 
their bizarre and sometimes frightening behavior, and—depend-
ing on the societal system—end up in special care homes, asylums 
or jails, on the street, or are even executed. Human Rights Watch 
(1) states that “US prisons and jails have taken on the role of 
mental health facilities” as a consequence of the “limited avail-
ability of community-based outpatients and residential mental 
health programs and resources.” In the USA, direct and indirect 
costs of schizophrenia amounted to approximately 62.7 billion 
in 2002 (2). Between 1.5 and 3% of the total national health-care 
expenditures are spent on patients with schizophrenia (3).
The pathophysiology of schizophrenia is still unknown (4). 
Standard therapies against schizophrenia are only symptomatic 
and provide control rather than cure (5). Antipsychotics, the 
standard drugs, are criticized because of severe side effects, 
including metabolic syndrome and brain atrophy (6, 7). More 
and more evidence supports the hypothesis that schizophrenia is 
a neurological disease rather than a psychosocial disorder. One 
important piece of evidence is the recent discovery of anti-NMDA 
receptor encephalitis (8), which causes psychotic states leading, 
in some cases, to a misdiagnosis of schizophrenia (9).
One of the most promising new research concepts is the mild 
encephalitis hypothesis of schizophrenia, developed mainly 
by the German psychiatrists, Karl Bechter and Norbert Müller 
(10–15). According to this hypothesis, a significant subgroup of 
patients with schizophrenia suffer from a mild, but chronic form 
of encephalitis which can have quite different etiologies ranging 
from viral infections, traumas to autoimmune diseases. At least 
in a subgroup of schizophrenia patients, inflammatory processes 
occur in the beginning or during the course of the disease (16–20). 
Therefore, anti-inflammatory drugs might be effective. Indeed, 
several small, but high quality studies have shown significant 
effectiveness of several anti-inflammatory drugs such as aspirin 
and N-acetylcysteine as add-on medication to antipsychotic 
drugs, particularly for first-episode psychosis patients (18, 20, 
21). Since different etiologies (genetically caused, immunologi-
cal, growth factor-related, acquired, etc.) can underlie psychotic 
symptoms, a careful differential diagnosis is necessary. The aim of 
this article is not to provide a comprehensive review, but to focus 
on arising ethical questions.
The mild encephalitis hypothesis implies that schizophrenia 
would no longer be considered an incurable psychiatric disorder, 
but instead, a chronic, and in many cases, treatable neurological 
disease. With this paradigm shift, significant consequences could 
be expected for (1) the theoretical conceptualization of schizo-
phrenia, which will challenge the psychiatric diagnostic systems, 
Diagnostic and Statistical Manual of Mental Disorders version 
5 (DSM-5) and ICD-10; (2) the medical discipline in charge of 
schizophrenia patients; (3) the diagnostic procedures; (4) the 
therapies; (5) the pharmaceutical industry; (6) the legal evalu-
ation of compulsory drug treatment; (7) the social inclusion of 
patients; and (8) the stigmatization of patients and their relatives.
We proceed with a general description of schizophrenia 
(part 2). Then, we present the mild encephalitis hypothesis of 
schizophrenia, discussing the available scientific evidence (part 
3). Finally, we investigate which consequences could be expected 
of the mild encephalitis hypothesis of schizophrenia, and evaluate 
these consequences ethically (part 4).
sCHiZopHrenia
The recent psychiatric diagnostic systems ICD-10 and DSM-5 
ground on a nominalistic concept of mental diseases, which is 
agnostic with regard to etiology and neuropathology.
Symptoms of schizophrenia are categorized into two classes: 
positive symptoms describe an excess of normal functions (e.g., 
delusions, hallucinations, disorganized speech, and behavior) 
and negative symptoms a decline or loss of normal functioning 
(diminished emotional expression or avolition).
The DSM-5 defines schizophrenia by six criteria (A–F) (22). 
Criterion A requires for the diagnosis of schizophrenia that at 
least two of five characteristic symptoms (1. delusions, 2. hal-
lucinations, 3. disorganized speech, 4. grossly disorganized or 
catatonic behavior, and 5. negative symptoms) are present for a 
significant portion of time during a 1-month period (or less if 
successfully treated). Criterion B refers to social/occupational 
dysfunction, and Criterion C defines the required duration of 
symptoms. Criteria D–F distinguish schizophrenia from other 
disorders. Particularly, Criterion E excludes a diagnosis of schizo-
phrenia if the disturbance is attributable to physiological effects of 
a substance or another medical condition.
Clinical Course
Psychotic features of schizophrenia typically appear between the 
late teens and mid-30s. Sustained recovery occurs in less than 
30%; relapse rates are very high and reach approximately 80% 
(4). In the majority of patients, the illness becomes chronic with 
severe social consequences: in Europe, only 20% of people with 
schizophrenia are employed. In the USA, 20% are homeless 
1 year after the diagnosis (4). Individuals with schizophrenia are 
at increased risk to become violent offenders (23). The risk of 
committing a violent offense is 4.6-fold increased in men, and 
even 23.2-fold in women (24).
People with schizophrenia have high comorbidity rates for 
further psychiatric disorders, particularly substance abuse, 
obsessive-compulsive disorder, and panic disorder (22).
Apart from psychotic symptoms, people with schizophrenia 
often suffer from inappropriate affect, disturbed sleeping pat-
terns, lack of interest in eating, somatic concerns, impulsiveness, 
reduced attention, and deficits in Theory of Mind (22).
Furthermore, schizophrenia is associated with general medi-
cal risk factors: a higher prevalence of obesity, diabetes mellitus 
(partly due to atypical antipsychotics), and hypertension. These 
risk factors lead to an elevated risk for chronic illnesses, such as 
coronary heart disease, metabolic syndrome, and pulmonary 
diseases (22).
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Patients with schizophrenia have twofold to threefold higher 
mortality rates compared to the general population. Life expec-
tancy is reduced by 10–25  years (25). Four main reasons con-
tribute to the higher mortality rate: comorbid physical illnesses, 
insufficient physical health care, adverse effects of antipsychotic 
medication, and suicides (25). Approximately 20% of patients 
with schizophrenia attempt suicide, while 5–6% die by suicide 
(22).
Genetic and environmental Factors
The heritability of schizophrenia is about 80%, but the search 
for its genetic basis has been frustrating (26). Schizophrenia is a 
polygenetic disorder. A genome-wide association study discov-
ered 108 schizophrenia-associated genetic loci, many of which 
are involved in important immune functions, particularly in 
acquired immunity (27). This finding is conceptually in line with 
the mild encephalitis hypothesis (13).
The vulnerability-stress model has been the prominent 
explanatory model for schizophrenia during the past decades (15). 
Neither the genetic code nor the environment is the sole cause 
for schizophrenia. Rather the effect of an individual’s genotype 
depends on environmental exposure and, vice  versa, the effect 
of environmental exposure on risk depends on an individual’s 
genotype (13, 26). The incidence of schizophrenia is twofold to 
fourfold increased in people living in or raised in urban areas, in 
migrant and minority ethnic groups, in cannabis users, and in 
people with childhood adversity (26).
neurotransmitter disturbances and 
reduced Brain Volume
Disturbances in neurotransmitters and receptors have been 
postulated for decades in diverse hypotheses of schizophrenia, 
especially imbalances in dopamine, glutamate, and serotonin 
systems. It is assumed that hypofunction of dopaminergic 
projections from mesolimbic to prefrontal structures causes 
negative symptoms and that a subcortical excess of dopamine 
is responsible for positive symptoms (28). The main source of 
serotonin, the dorsal raphe nucleus, is hypothesized to be chroni-
cally upregulated due to stress in schizophrenic patients; this can 
influence glutamatergic transmission and inhibit dopaminergic 
neurons, thus causing negative symptoms (29).
Magnetic resonance imaging (MRI) studies demonstrated a 
progressive loss of brain volume in patients with schizophrenia. 
Both gray and white matter damage is already present in prodro-
mal and first-episode psychosis patients (6, 7). The reduction of 
gray matter is associated with elevated peripheral inflammatory 
markers (7). However, findings of MRI studies are valid on a 
group level, and do not allow individual diagnoses.
treatment
First-generation antipsychotic agents (FGA, typical antipsychot-
ics), such as haloperidol, fluphenazine, and chlorpromazine, 
exert their effects by blocking dopamine receptors and thus 
decreasing mainly positive symptoms (30). However, FGAs 
have severe side effects, e.g., deterioration of negative symp-
toms and cognition, prolactin elevation, acute and chronic 
movement disorders, such as tremor, rigidity, and tardive 
dyskinesia (30).
Second-generation antipsychotic agents (SGA, atypical antip-
sychotics), e.g., clozapine, olanzapine, and quetiapine also block 
dopamine receptors, but additionally influence serotonin and 
norepinephrine receptors, which makes them more effective 
against negative symptoms (28, 30). While SGA do not evoke the 
typical FGA side effects, they have other severe adverse effects 
such as agranulocytosis (reduction of white blood cells), weight 
gain, and alterations in glucose and lipid metabolism (30).
Although brain volume of schizophrenic patients is already 
reduced before the beginning of antipsychotic medication, both 
FGAs and SGAs seem to increase this effect (6, 7). The cumula-
tive antipsychotic medication can cause neurocognitive decline, 
negative and positive symptoms, and worsen psychosocial func-
tioning (6). Cognitive deficits and negative symptoms respond 
only modestly to antipsychotic medication (4). Neither FGAs nor 
SGAs improve functional recovery (e.g., employment) (4).
Anti-epileptic agents can be added for reducing aggression 
and impulsiveness, and antidepressants to reduce depression, 
anxiety, and if necessary craving for drugs.
Psycho-educational and coping-oriented interventions, 
cognitive behavioral therapy, cognitive remediation, social skills 
training, and assertive community treatment can help patients 
to reintegrate and participate in the community (30). Supportive 
therapies for family members and patients can enhance medica-
tion adherence and help to cope with persistent psychotic symp-
toms (30).
tHe MiLd enCepHaLitis HypotHesis 
oF sCHiZopHrenia
The hypothesis that infections could play a part in the develop-
ment of schizophrenia is not new: the association between 
bacterial infections and psychosis was already proposed in 1896 
(31). Later on, psychosis and schizophrenic symptoms were 
hypothesized as consequences of the influenza pandemia in 1918. 
Unfortunately, these theories were not further investigated due 
to a lack of relevant treatment methods and the growing promi-
nence of Freudian theories (31). Today, the role of inflammation 
in psychiatric disorders has become one of the most promising 
research fields (21).
The mild encephalitis hypothesis published by Karl Bechter in 
2001 and updated in the following years, explains the pathophysi-
ology of a subgroup of severe psychiatric disorders, especially 
of schizophrenic and affective psychoses, in terms of a mild 
encephalitis. This hypothesis is based on findings from immu-
nology, cerebrospinal fluid (CSF) investigations, imaging studies, 
and clinical observations. Mild encephalitis is a non-lethal, low 
grade cellular-infiltrative and/or humoral brain inflammation, 
possibly accompanied by neurological soft but not hard signs 
(12). The demarcation between “classical” encephalitis and “mild” 
encephalitis is important, since “mild” points to the so-called 
“low-level neuroinflammation” (12). This term is used in clinical 
publications to describe molecular or cellular abnormalities of 
minor degree (12).
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According to the mild encephalitis hypothesis, the reduced 
brain volume of schizophrenia patients could be a consequence 
of mild inflammatory states, which are caused by trauma or 
various types of toxicity (12). Indeed, elevated cytokine levels 
are correlated with brain volume loss (7, 12, 14). Inflammation 
can also disturb brain development of unborn children: during 
the second half of pregnancy, maternal levels of serum IL-8 
(sensitive inflammatory marker) are associated with decreased 
cortical volumes and an elevated risk for schizophrenia in the 
offspring (14).
A multitude of factors can trigger mild inflammation, e.g., 
infections, autoimmunity, toxicity, and trauma; this is modulated 
by genetic and environmental factors, and immune status (12).
Several lines of evidence support the mild encephalitis 
hypothesis of schizophrenia.
 1. Patients with schizophrenia have increased levels of certain 
inflammatory markers.
 2. Inflammatory processes in the brain can disturb neurotrans-
mitter metabolism.
 3. Infections, both prenatal and postnatal, can increase the risk 
of schizophrenia.
 4. There is a correlation between autoimmune diseases and 
schizophrenia which could be linked to inflammatory events.
inflammatory processes
According to the vulnerability-stress model of schizophrenia, 
physical and mental stress can cause psychotic episodes. 
Inflammation could be the missing link between stress and 
psychosis (15). Stress deteriorates the body’s ability to fight 
infections, triggers autoimmune activity (32), and increases 
the production of pro-inflammatory cytokines (15, 16, 31, 
33). Pro-inflammatory cytokines are key regulators of inflam-
mation, whereas anti-inflammatory cytokines can inhibit the 
production of their pro-inflammatory counterparts. Cytokines 
can affect neurotransmitter levels and microglial activation 
(33). Microglial cells fight invading antigens, influence growth 
and apoptosis of neural cells, and can produce cytokines (19). 
Microglia can be “primed” so that they respond even to a small, 
second stimulus (14, 15). Thus, cytokine production by micro-
glia can become chronic and also proceed in the absence of the 
initial trigger.
Schizophrenic patients seem to be in such a heightened 
inflammatory state: in non-medicated schizophrenic patients, 
cytokine levels are increased (15, 19). Activated microglia have 
been detected in patients with recent-onset schizophrenia (15).
infections
Maternal immune activation is an important risk factor for 
schizophrenia and autism in the offspring (15, 34). Inflammation 
during pregnancy could alter normal neurodevelopment, gene 
expression, and immune function in the unborn child (34–36). 
Epidemiological studies, prospective birth studies, and animal 
studies support the hypothesis that maternal immune activa-
tion can cause life-long neuropathology and altered behavior 
in the offspring. Most maternal infections act as a disease 
primer (“first hit”) making the individual more susceptible to 
the effects of genetic mutations and environmental exposures 
(20, 34).
CNS infections in childhood and in adulthood also elevate the 
risk of schizophrenia (20, 31). Likely, in both prenatal and post-
natal infections, the schizophrenia risk is rather elevated by the 
immune response (inflammatory cytokines, antibodies), instead 
of a specific pathogen being responsible for the disease (15, 31, 
34–36). As a matter of fact, the risk of developing schizophrenia 
is associated with the number of severe infections, following a 
dose–response relationship (31).
Nevertheless, infections with the parasite Toxoplasma gondii 
play a special part in schizophrenia. According to a recent meta-
analysis, the evidence for an association between schizophrenia 
and T. gondii is “overwhelming” (37): the prevalence of T. gondii 
antibodies is 1.43-fold higher than in controls (37). A similar asso-
ciation exists for obsessive–compulsive disorder, bipolar disorder, 
and possibly addiction (37). Presumably, a latent infection with T. 
gondii is reactivated in patients with schizophrenia. The underly-
ing mechanism might be T. gondii increases the concentration of 
dopamine in the brain (38). Toxoplasma-infected schizophrenia 
patients have more severe delusions and a reduced gray matter 
density in certain parts of the brain compared to Toxoplasma-free 
patients (38).
autoimmunity
People with several autoimmune diseases have an elevated 
risk of developing schizophrenia, and vice  versa. There are 
correlations between schizophrenia and many autoimmune 
diseases, e.g., multiple sclerosis, type 1 diabetes, celiac disease, 
autoimmune thyroiditis, autoimmune hepatitis, systemic lupus 
erythematosus, Crohn’s disease, psoriasis, and Guillan–Barré 
syndrome (32). Multiple sclerosis and schizophrenia might 
even have similar pathogenetic mechanisms (15). Moreover, 
multiple sclerosis can at times predominantly present itself with 
psychiatric features (13).
Linking factors between schizophrenia and autoimmune 
diseases might be inflammatory events and their consequences 
(increased permeability of the blood–brain barrier and the 
intestinal wall, brain-reactive antibodies, increased levels of 
inflammatory cytokines, and primed microglia) (32). Another 
explanation might be a genetic vulnerability for dysfunctions of 
the immune system (32). The correlations between autoimmune 
disorders and schizophrenia fit well with the mild encephalitis 
hypothesis, which supposes autoimmunity as a possible trigger 
for mild inflammatory processes (12).
autoimmune encephalitis
Schizophrenia shares commonalities with autoimmune 
encephalitis, first described in 2008 (8). In autoimmune 
encephalitis, antibodies attack neural brain structures 
(9, 39). For example, anti-NMDA receptor encephalitis is 
caused by immunoreactivity against a specific part of the 
NMDA receptor (9, 39). The disease primarily affects females 
in early adulthood and is accompanied by a tumor in approxi-
mately 50% of cases, in this patient group (39). Healthy con-
trols were also found to carry NMDA receptor antibodies, with 
increasing prevalence depending on age, making the presence 
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of antibodies insufficient for the diagnosis of anti-NMDA 
receptor encephalitis (40).
Nowadays, additional types of autoimmune encephalitis have 
been uncovered targeting different neurotransmitter receptors, 
channel complex associated proteins or other cell structures (39). 
A growing number of neural antibodies can be detected, due to 
improved laboratory methods (13).
In anti-NMDAR encephalitis, psychiatric features such as 
psychosis, confusion, and aggressive behavior are often pre-
dominant in the initial phase; hence, patients are initially treated 
in psychiatric facilities (9). However, as the disease progresses, 
neurological symptoms, such as tongue thrusting, cheek biting, 
sucking of lips, hyperkinesia, rigidity, involuntary, stereotyped 
movements, and spasms, increase. Late stages of the disease are 
characterized by decreased consciousness and dysregulation of 
the autonomic center with hyperthermia, elevated heart rate, and 
reduced breathing (39). Patients can often be treated successfully 
with immunosuppressive agents such as steroids, intravenous 
immunoglobulins, and plasmapheresis. Second-line therapy 
includes pharmacological agents used in cancer treatment and 
autoimmune disease (9, 39).
Endres et  al. (41) found CSF and autoantibody abnormali-
ties in 54.4% of 180 psychotic patients. Bechter (13) found that 
pathological measures (immunoglobulines, elevated cell counts, 
inflammatory cytokines, and blood-barrier dysfunctions) in CSF 
of 41% of schizophrenic and affective spectrum disorder patients, 
with lower level CSF abnormalities detected in 79% of severe, 
treatment-resistant cases. Several further studies investigated 
the prevalence of autoantibodies targeting neural structures in 
schizophrenia patients, psychiatric patients in general and con-
trols, whereby the results are complex and difficult to interpret 
(40, 42–45). Presumably, the loss of blood–brain barrier integrity 
contributes to NMDAR antibody pathologies (40, 43). Antibody-
associated mechanisms may be a transient phenomenon in 
schizophrenia (9), and the concurrent presence of autoantibod-
ies is suggestive of a mild form of encephalitis syndrome (44). 
Antibody positivity may express itself as a continuum, ranging 
from relatively “pure” psychotic presentations to catatonia and 
potentially moribund encephalitis (44).
Just recently, in Germany, the death of a polar bear (ursus 
maritimus) of the Berlin Zoological Garden, received nation- 
and worldwide attention: the polar bear, called “Knut,” drowned 
in 2011 due to seizures and was diagnosed with anti-NMDAR 
encephalitis post-mortem (46). Knut is the first non-human 
case of anti-NMDAR encephalitis. It received extensive media 
coverage and made autoimmune encephalitis known to the wider 
public.
anti-inflammatory drugs
The mild encephalitis hypothesis is reinforced by clinical stud-
ies finding therapeutic benefits when anti-inflammatory agents 
were added to the antipsychotic medication of schizophrenic 
patients (18, 20, 21). A meta-analysis of 26 randomized, placebo-
controlled double-blind studies describes significant effects for 
aspirin, estrogens, and N-acetylcysteine (NAC, cough syrup) 
with low to moderate effect sizes (18). Estrogens seem to be effec-
tive only in female patients (16, 18); presumably, its effects are 
hormonal. No statistically significant effects are found for mino-
cycline (antibiotic agent), and omega-3 poly-unsaturated fatty 
acids (omega-3 PUFAs) (18, 20, 21). However, these substances 
were shown to be effective in subgroups of patients, particularly 
in first-episode psychosis patients. Results for celecoxib [a selec-
tive cyclooxygenase-2 (COX-2) inhibitor] show a significant 
advantage in the same subgroup of patients (20, 47). Due to 
promising but inconclusive effects, further research on these and 
other anti-inflammatory drugs is necessary.
In a small pilot trial, Tocilizumab, an IL-6 receptor monoclonal 
antibody, was added to antipsychotics, showing positive effects on 
cognition without clinically significant side effects [(48), http://
ClinicalTrials.gov identifier NCT01696929].
A recent Cochrane study reviewed the effectiveness of anti-
glucocorticoid substances including 11 studies with 509 patients 
with psychotic disorders and found some positive effects for 
mifepristone, although the current data is insufficient to give clear 
recommendation (49).
A review on nutritional interventions summarizes clinical 
trials with adjunctive substances, such as antioxidants, vitamin B 
supplements, neuroprotective, and anti-inflammatory nutrients 
(alpha-lipoic-acid, melatonin, NAC, vitamin C and E, PUFAs, 
l-Theanine), as well as exclusion diets (casein-free, glutein-free 
diet). Based on the reviewed findings, the authors recommend 
personalized food supplementation, because this strategy could 
help detect and treat the nutritional deficiencies and food intol-
erances often encountered in patients. Furthermore, nutritional 
supplementation could ameliorate symptoms of schizophrenia in 
some patients (50).
Generally, the effect strength of anti-inflammatory drugs 
is shown to be greater in first-episode psychosis patients (18). 
This supports the assumption that inflammatory processes play 
an important part mainly in the early phase of mild encephalitis 
schizophrenia.
However, most of these drugs not only exert anti-inflammatory 
effects, but have further effects that might additionally or alterna-
tively explain their efficacy in schizophrenia: (1) influences on the 
transmission of dopamine (estrogens, NAC), glutamate (NAC) 
or serotonin (omega-3-PUFAs), (2) effects on the gut microbiota 
(minocycline), (3) influence on the body’s stress system (aspirin), 
(4) neuroprotection (omega-3-PUFAs), (5) enhanced neurogen-
esis (omega-3-PUFAs), and (6) influence on the composition of 
cell membranes (omega-3-PUFAs) (16, 18, 21, 51).
inflammatory status in other psychiatric 
disorders
Inflammatory events could also play an important part in 
the development of bipolar disorder, major depression, and 
obsessive–compulsive disorder (21, 33, 52–55). Furthermore, 
neuroinflammation potentially contributes to neurodegenerative 
diseases, such as Alzheimer’s disease, Parkinson’s disease, amyo-
trophic lateral sclerosis, and frontotemporal dementia (56). Some 
forms of autoimmune encephalitis can even mimic Alzheimer’s 
disease (57, 58).
Patients with mood disorders suffer more frequently from 
autoimmune disorders, e.g., multiple sclerosis and diabetes 
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(3-fold higher prevalence), rheumatoid arthritis, systemic 
lupus erythematosus, and inflammatory bowel disease (33). 
For example, bipolar disorder is accompanied by several sys-
temic chronic diseases, such as artherosclerosis, hypertension, 
diabetes, and obesity, which are triggered by inflammatory 
processes (53). Anti-inflammatory agents (COX-2 inhibitor, 
acetyl-salicylic acid, fatty acids, and minocycline) are thera-
peutically effective in patients with bipolar disorder and major 
depression (33).
schizophrenia as a systemic disease
According to the mild encephalitis hypothesis, schizophrenia 
is a systemic disease with preferential involvement of the brain 
rather than an exclusive brain disease (12, 20, 53). The link 
between pathologies both in the brain and in the residual body 
could be the CSF. CSF is produced by the choroid plexus, fills 
the ventricles and the area around the spinal cord, flows along 
cranial and spinal nerves, and comes into contact with muscular, 
subcutaneous, and peripheral neural tissue (12). In 41% of schiz-
ophrenic and affective spectrum disorder patients, CSF showed 
pathological signs (immunoglobulines, elevated cell counts, 
inflammatory cytokines, and blood-barrier dysfunctions), and 
79% of severe, treatment-resistant cases had CSF abnormalities 
of low level degree (13). Inflammatory messengers likely spread 
via the peripheral cerebrospinal outflow pathway from the CNS 
to peripheral body compartments. This mechanism could also 
explain sensory hallucinations experienced by many patients 
(12). In a study of 180 psychotic patients, 54.4% displayed CSF 
and autoantibody abnormalities (41).
The understanding of schizophrenia as a systemic disease is 
further upheld by research on the gut microbiome: inflamma-
tory bowel diseases, such as ulcerative colitis, Crohn’s disease, 
and irritable bowel syndrome, have a more than 10-fold higher 
incidence in schizophrenia patients (3.4%) compared to controls 
(0.3%) (59).
Furthermore, the microbiomes of the oropharynx, pharynx, 
and intestinal organs differ between schizophrenia patients 
and controls (59, 60). By profiling oropharyngeal microbiomes 
with metagenomic sequencing, patients with schizophrenia can 
be distinguished from controls (60). Hence, a biomarker based 
on gut microbiota is conceivable (59, 60), and research in this 
area might facilitate the development of a laboratory test for 
schizophrenia.
etHiCaL issUes oF tHe MiLd 
enCepHaLitis HypotHesis
If the mild encephalitis hypothesis was further strengthened 
by clinical evidence, major consequences would have to be 
expected for (1) the theoretical conceptualization of schizo-
phrenia, (2) the appropriate medical discipline for schizo-
phrenia, (3) the diagnostic procedures, (4) the treatment, (5) 
the pharmaceutic industry, (6) compulsory treatment, (7) the 
patients’ social inclusion, and (8) the stigmatization of patients 
and their relatives.
In the following, we analyze the expected consequences 
ethically.
theoretical Conceptualization of 
schizophrenia
The diagnostic term “schizophrenia” can be compared to the 
umbrella term “bellyache,” for didactic purposes. Rather than 
delineating certain organs, functional units, and mechanisms that 
cause the characteristic symptoms, its definition is based solely on 
symptoms, regardless of their possible causes (4). In an analogous 
way, the umbrella term “bellyache” describes pain in the abdo-
men, regardless of its anatomical position, e.g., gastrointestinal 
tract, Fallopian tube, or the liver, and regardless whether it is 
caused by infection, autoimmune processes, or poisoning.
Since schizophrenia is not a disease entity, but an umbrella 
term for different pathologies with common symptoms, sub-
groups of schizophrenia are feasible; e.g., “schizophrenia should 
be deconstructed” (61). One subgroup may be caused by mild 
encephalitis.
For a diagnosis of schizophrenia, DSM-5 requires that the 
disturbance is not attributable to “another medical condition” 
(criterion F). Defining “bellyache” analogously, this term could 
not be used as soon as the pain was attributable to a disorder 
of the stomach listed in DSM or ICD. The DSM-definition of 
schizophrenia makes it nearly impossible to explain schizo-
phrenia by reducing the disease to a biological mechanism, 
since any mechanism would be considered “another medical 
condition.” This would automatically exclude the diagnostic term: 
“schizophrenia.” For example, if a patient is diagnosed with mild 
encephalitis (or, in fact, any other organic pathology), a diagnosis 
of schizophrenia can no longer be applied (44). Although mild 
encephalitis is not yet defined as a disease in the ICD-10, it would 
supposedly be considered a “medical condition” as soon as it was 
acknowledged that it can cause symptoms of schizophrenia. From 
that point on, the diagnosis “schizophrenia” could no longer be 
applied to patients with mild encephalitis.
The psychiatric classification systems DSM-5 and ICD-10 
have often been criticized as “descriptive taxonomy based on 
expressed feelings and observed behavior” (62), as being agnostic 
on the etiopathogenesis of disorders (63), since its diagnostic 
tools are insufficiently based on a biomedical understanding of 
mental illness ((64)). The etiology of psychiatric disorders cannot 
be elucidated by psychopathology itself (13). The nominalistic 
approach of the DSM also poses an obstacle for research, slowing 
the progress of psychiatric science. For example, one reason for 
the lack of reliable biological tests for psychiatric disorders is the 
dependence of research criteria on the often too superficial DSM 
criteria (63).
The Research Domain Criteria (RDoC) project of the National 
Institute of Mental Health is being developed as an alterna-
tive classification system to the DSM-5 system, especially for 
researchers. The aim of this project is to classify mental disorders 
based on dimensions of observable behavior and neurobiological 
measures, e.g., genes, molecules, cells, circuits, physiology, behav-
ior, and self-reports (63, 65). The RDoC could set the foundation 
for a classification system in which descriptive taxonomy is 
supported by a biomedical understanding of mental illness. This 
would further reduce the concerns that psychiatry is merely a tool 
for social control (64). The main elements of the mild encepha-
litis hypothesis of schizophrenia could be easily integrated into 
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appropriate RDoC sections, particularly the sections “molecules,” 
“cells,” and “physiology.”
the appropriate Medical discipline for 
treating schizophrenia
The question of the medical discipline in charge of psychotic 
patients has far-reaching consequences for the diagnosis, treat-
ment and life-long health care of patients. If patients do not 
present hard neurological signs such as epilepsy or movement 
disorders, they are normally hospitalized in psychiatry and 
diagnosed according to DSM-5 or ICD-10. Many psychiatrists 
do not routinely perform full physical examinations, since they 
are less aware of somatic causes of mental illness. Somatic illness 
is usually addressed as comorbidity, instead of being seen as a 
symptom of schizophrenia. Only if patients present hard neuro-
logical signs, they are referred to neurology, where they undergo 
CSF analysis, EEG, anti-neural antibody titer analysis, and brain 
imaging.
This kind of differentiation can become precarious, e.g., for 
patients with anti-NMDAR encephalitis. Initially, and sometimes 
throughout the whole course of disease, they may exclusively 
present psychiatric symptoms and are consequently hospitalized 
in psychiatric hospitals (9). Since blood tests and CSF analysis for 
anti-neural antibodies are not standard diagnostic tools in most 
psychiatric clinics, these patients are at risk of being diagnosed 
with schizophrenia. As a result of ineffective treatment, they 
might suffer severe, permanent brain damage or die. Indeed, 
several cases of patients with anti-NMDAR encephalitis and mis-
diagnosed with schizophrenia have been reported (42). Somatic 
examination and adequate antibody screening should become 
standard procedure in first-episode psychosis patients in order to 
find possible organic causes (9, 52, 54, 55, 66).
We recommend treating psychotic patients primarily in 
interdisciplinary teams, optimally in neuropsychiatric units. 
Psychiatric expertise is necessary for adequately dealing with 
severe behavioral symptoms and for psychotherapeutic treat-
ment. Neurological expertise is necessary for CSF analysis, 
imaging data, and further neurological examination in order to 
adequately identify treatable organic causes (9, 13). Knowledge 
from both disciplines is needed for optimal, personally tailored 
pharmacotherapy. Causal therapies might target, e.g., teratomes, 
parasites, infectious agents, or autoimmune processes. Treating 
mental illness continuously over longer periods of time is 
especially challenging since symptoms, such as denial of illness, 
paranoia, irrational thoughts, deficits in executive function, and 
disruptive behavior, are often complicating factors (4). Therefore, 
it is of great importance that patients in early stages of the disease 
swiftly receive interdisciplinary diagnostics followed by appropri-
ate, possibly causal, treatment.
If more evidence in favor of a mild encephalitis component in 
schizophrenia was gathered, the diagnostic procedure for patients 
with psychotic outbreaks would have to change significantly. 
Three different developments are possible: first, the responsibility 
for patients with schizophrenia would shift from psychiatry to 
neurology as it has happened with dementia. Second, the mild 
encephalitis hypothesis of schizophrenia would contribute to a 
reunion of psychiatry and neurology. Third, it would support 
interdisciplinary treatment concepts for schizophrenia.
In addition to psychiatrists and neurologists, internists, and 
when necessary experts for endocrinology, diabetology, and car-
diology should be consulted for somatic comorbidities of schizo-
phrenia, e.g., hypertension, obesity, diabetes mellitus, nicotine 
dependence, and dyslipidemia. This is of particular importance 
since physical illnesses are mainly responsible for the twofold to 
threefold increased mortality rate (25).
To reduce these high mortality rates of patients with schizo-
phrenia and to adequately address their special medical condition, 
an integrated service provision is required (67). The coordination 
of mental and physical treatment could be managed by care 
coordinators (25, 67). Compared to standard care, patients in 
comprehensive community care settings showed better clinical 
and functional outcomes (68).
diagnostic procedure
As traditional classification systems such as DSM or ICD will not 
undergo radical change in the near future, biomedical tests should 
be added to the existing diagnostic schemes. A first example is the 
biomarker for schizophrenia based on the gut microbiota (59, 60). 
Progress in genomics, medical imaging, molecular biology, and 
cognitive sciences could aid in the development of reliable tests 
to accurately diagnose psychiatric disorders and to predict treat-
ment response to specific drugs (4, 20, 62, 64). Several diagnostic 
procedures are recommended based on the mild encephalitis 
hypothesis.
The International Encephalitis Consortium recommends 
methods such as the investigation of CSF and serum, MRI, EEG 
and neurologic examination for diagnosing acute encephalitis 
(69). However, for mild encephalitis, a standard diagnostic 
procedure does not yet exist, because relevant changes in disease 
indicators are small and unspecific, making it difficult to set 
cut-offs and to detect pathologies (12). Nevertheless, standard 
diagnostic procedures for acute encephalitis could be adopted 
for mild encephalitis.
For detecting acute encephalitis, it is recommended to test 
paired CSF-serum samples for routine parameters, infectious 
agents, autoantibodies associated with autoimmune encephalitis, 
and immunoglobulins (69). Similarly, the gold standard for 
diagnosing schizophrenia of the mild encephalitis type is the 
investigation of CSF, since it allows the detection of even minor 
pathological abnormalities (12, 13).
CSF and Serum Investigation
Cerebrospinal fluid investigation is the most precise method 
for detecting inflammation in the central nervous system (13). 
Although it is not recommended in most guidelines, there are 
strong arguments for a systematic CSF screening of psychotic 
patients, especially prior to initiating psychopharmacological 
treatment (13, 41). With the help of CSF analysis, most neurologi-
cal disorders can be excluded (13). However, lumbar puncture is 
not without risks. The most frequent complication is headache 
(36.5–60%). Rare complications are brain herniation, cardiores-
piratory compromise, local or referred pain, hemorrhage, suba-
rachnoid epidermoid cyst, and CSF leak. Serious adverse events 
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caused by infectious agents (e.g., meningitis) occur in <1% (70). 
When comparing the medical risks and the financial cost with 
the benefits of routine lumbar puncture in psychotic patients, 
the benefits overweigh, especially since CSF analysis offers the 
possibility for an effective, causal treatment.
Autoimmune Encephalitis
Each patient with psychosis should be tested for autoimmune 
encephalitis via routine screening for antibodies and inflamma-
tory parameters in serum and CSF, particularly in a first-episode 
psychotic outbreak. This is necessary to avoid misdiagnosis and 
consequent inappropriate treatment possibly resulting in long-
term disability or even death (41, 66). Patients with pathogenic 
antibodies can be detected only by screening all first-episode 
psychosis patients for antibodies (45). With the help of improved 
laboratory methods to measure antibodies, an increasing number 
of neural offenders will become detectable (13).
Red flags in the psychopathological status clinically pointing 
to autoimmune encephalitis, are movement disorders, disturbed 
consciousness, hyponatriemia, a rapid disease progression, cata-
tonic symptoms, comorbid autoimmune diseases (Hashimoto 
thyroiditis), focal neurological deficits, MRI-, CSF- and EEG 
abnormalities, and a very acute disease onset (13). Since not all 
relevant autoantibodies are known yet, autoimmune encephalitis 
may be present even if tests for all known autoantibodies are 
negative. In this case, brain biopsy might confirm autoimmune 
encephalitis (52).
Disease-specific antibodies for schizophrenia have neither 
been found in serum nor in CSF (39). In a minority (8%) of 
schizophrenia patients, NMDAR antibodies are detectable, 
although they differ from those required for a diagnosis of anti-
NMDAR encephalitis (44). These autoantibodies were found 
in patients with a first episode of psychosis, but not in chronic 
patients (44). Most likely, autoantibody-associated mechanisms 
are a transient phenomenon in schizophrenia (9). The presence of 
autoantibodies in some patients with schizophrenia suggests that 
these patients have a mild form of encephalitis (44). Whether an 
individual develops only psychotic symptoms or the full encepha-
litic syndrome may depend on several factors such as antibody 
subtype, antibody titer, brain area affected or blood-brain barrier 
integrity (40, 44).
Brain Imaging
In acute encephalitis, MRI can assist to detect abnormalities, 
demyelination or necrotic lesions, helping to illuminate the 
pathogenesis (39, 69). However, in mild encephalitis, MRI is not 
sensitive enough to reliably detect minor lesions and inflammation 
(12). Nevertheless, signs of mild atrophy, minor local intensities 
or local swelling could indicate states of mild inflammation (12). 
Fluorodeoxyglucose positron emission tomography is an impor-
tant screening tool for yet undetected, but underlying tumors 
such as teratomas or lymphomas, which can produce antibodies 
causing psychosis (39). Furthermore, with the advanced dynamic 
contrast-enhanced MRI, blood-brain barrier disruptions can be 
investigated (40). Due to good availability and low side effects, 
neuroimaging is an appropriate method for excluding major 
brain pathologies (13).
treatment
Since the pathophysiology of schizophrenia is still unknown, 
curative treatment or preemptive interventions are missing (4). 
Current treatments provide control rather than cure (5). The 
mild encephalitis hypothesis could change the treatment of 
schizophrenic patients considerably.
Reducing inflammation is the most important therapeutic 
consequence of the mild encephalitis hypothesis. It is the prereq-
uisite for controlling both mental symptoms and the comorbidity 
“metabolic syndrome,” which itself is also associated with mild 
and chronic inflammation (17, 20). Several treatment strategies 
are under investigation.
Food Supplements
Fishoil (omega-3 PUFAs) might be a preventive drug for patients 
with a high risk for developing schizophrenia. In a randomized, 
double-blind, placebo-controlled trial with high risk individu-
als aged 13–25, intervention with omega-3 PUFAs reduced the 
risk of progression to psychosis as well as psychiatric morbidity 
(follow-up 6.7  years). Only about 10% (4/41) in the omega-3 
PUFA group transitioned to psychosis, compared to 40% (16/40) 
in the placebo group (5). Additionally, omega-3 PUFAs reduced 
positive and negative symptoms, and improved functioning 
compared to placebo (5, 51). The number needed to treat was 4, 
which is comparable to atypical antipsychotics (51). The effec-
tiveness of omega-3 PUFAs has also been confirmed for (major) 
depression by a large meta-analysis (71). Omega-3 PUFAs are 
key components of brain tissue and, therefore, essential for 
neural development and function. Presumably, they influence 
membrane fluidity, receptor responses and modulate dopamine, 
noradrenaline, and serotonin levels (51). Furthermore, they have 
anti-inflammatory and anti-apoptotic potential (5). Possible 
side effects of omega-3 PUFAs, concerning the gastrointestinal 
tract, are only mild. The advantages of omega-3 PUFAs are their 
excellent tolerability, public acceptance, relatively low costs, and 
benefits for general health (21, 51).
Additionally, food supplementation with Vitamine C and 
Ginkgo biloba showed significant effects compared to placebo 
(20, 72).
Anti-inflammatory Medication
Anti-inflammatory medication seems to effectively target the 
underlying inflammatory states present in a subgroup of patients 
with schizophrenia (12, 17, 18, 20, 21, 47). Add-on of this treat-
ment regimen was found to be most effective in first-episode 
psychosis and influenced by the initial inflammatory status of 
the patient. Therefore, anti-inflammatory medication could be a 
cause-targeted therapeutic strategy in early phases of the disease 
to stop its progression (16, 21).
Nevertheless, undesirable side effects have to be considered: 
aspirin can cause gastrointestinal bleeding; a complication to 
be avoided by adding gastric protection (16, 18). All in all, the 
benefit–risk ratio for aspirin is in favor of the prescription (21). 
NAC (cough syrup), has negligible side effects and offers specific 
benefits: it can be administered during pregnancy, and might 
reduce substance abuse, a frequent comorbidity in patients (22). 
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This makes NAC ideally suited as the first-line anti-inflammatory 
agent against schizophrenia (16, 18).
Celecoxib has rare but severe cardiovascular and gastrointesti-
nal side effects, and should therefore be administered only in acute 
episodes rather than as long-term medication (21). Minocycline, 
though positively evaluated in animal and laboratory studies, 
cannot be recommended as first-line add-on agent because of its 
unclear efficacy and its significant risks (18, 20, 21).
At the moment, it is difficult to draw strong conclusions about 
the efficacy and safety of anti-inflammatory agents (16). Thus, no 
recommendations can be made in general (13). From an ethical 
point of view, NAC and aspirin can be recommended because of 
significant effectiveness and good tolerability; omega-3 PUFAs 
can be recommended because of a good benefit-risk ratio. Two 
patient groups might especially benefit from add-on of anti-
inflammatory medication: schizophrenic patients with predomi-
nant immune alterations, and second, first-episode psychosis 
patients (16, 61). These two patient collectives should be included 
in future studies as a first step toward personalized medicine for 
schizophrenia (16, 20, 61).
Ongoing clinical studies include, e.g., studies on aspi-
rin (http://ClinicalTrials.gov identifier: NCT02685748; 
NCT02047539), Siltuximab (IL-6 monoclonal antibody, 
NCT02796859), Tocilizumab (IL-6 receptor monoclonal anti-
body, NCT02874573), and l-tetrahydropalmatine (dopamine 
antagonist, NCT02118610), Withania somnifera (immunomodu-
lator and anti-inflammatory agent, NCT01793935). Trials 
adding substances to conventional therapies are under current 
investigation, with promising results, e.g., statines, metotrexate 
(immunosuppressive and anti-inflammatory agent), glucocorti-
coids, ibuprofen, and salsalate (non-steroidal anti-inflammatory 
drug) (20).
Antipsychotics
Apart from their evident anti-dopaminergic characteristics, 
antipsychotics might be effective in schizophrenia due to their 
anti-inflammatory properties (16, 17, 33). However, many patients 
refuse antipsychotics due to side effects, particularly in the long 
run (28, 51, 64). Since the benefit-risk ratio of antipsychotics is 
unsatisfactory, they should be administered for the shortest time 
and the lowest dose necessary to avoid severe side effects (6).
CSF Filtration
Cerebrospinal fluid filtration could be an add-on therapy in 
severe therapy-resistant schizophrenic and affective spectrum 
psychoses with immunological genesis (11). The risks of CSF 
filtration are justifiable in light of the reduced quality of life and 
high suicidal risk of psychotic patients (11).
Consequences for the pharmaceutic 
industry
Current pharmacological treatment options for schizophrenia 
(mainly antipsychotics) are merely symptomatic, not curative, 
with limited effectiveness and tolerability. They cannot improve 
functional recovery, and relapse rates are still about 80% (4). 
Therefore, better drugs are urgently needed. In agreement with 
the mild encephalitis hypothesis, drug development focusing on 
suppressing inflammatory processes might finally open the door 
to curative treatment.
The main challenge in developing an appropriate anti-inflam-
matory agent is the agent’s ability to pass the blood–brain barrier.
Current available agents known to cross the blood-brain barrier 
include: antipsychotics, celecoxib, estrogens, omega-3-PUFAs, 
minocycline and NAC (18). Aspirin, monoclonal antibodies, and 
corticosteroids are less able to reach the CNS (18). Despite vary-
ing treatment response, older, existing anti-inflammatory drugs 
with expired patent protection (e.g., NAC, aspirin, celecoxib) 
could partly replace the more expensive antipsychotic drugs. As 
there is little incentive for research on old drugs with expired 
patent protection or cheap food supplements (e.g., omega-3 
PUFAs, fishoil), further drug development will likely have to be 
state-funded.
However, as elaborated above, established anti-inflammatory 
drugs have a varying efficacy in schizophrenia, and entirely novel, 
more effective and well tolerable drugs are urgently needed. The 
demand for new, anti-inflammatory drugs would have significant 
impact for the pharmaceutical industry. The necessary research 
would be much more expensive than research on existing drugs. 
Therefore, depending on the economic and legal conditions of 
different countries, this research should be conducted by univer-
sities, and, if necessary, in combination with the pharmaceutical 
industry.
Compulsory treatment
In response to the UN Convention on the Rights of Persons with 
Disabilities (73), many countries have modified their laws in order 
to protect psychiatric patients from being treated compulsorily. 
For example, the German Federal Constitutional Court acknowl-
edged the “freedom to be ill” in several court rulings on forensic 
patients, diagnosed with schizophrenia, resisting compulsory 
treatment with antipsychotics. Besides these individual decisions, 
the Court decided that the federal laws allowing compulsory drug 
treatment were unconstitutional. German state parliaments were 
urged to reformulate their civil commitment laws and implement 
stricter legal conditions for compulsory treatment. In particular, 
compulsory treatment was limited to patients incapable of con-
sent; justified by the argument that the freedom to be ill must not 
be considered detached from the real capacities of free decision-
making which may be limited by illness (74).
Although legislation in most Western countries increasingly 
gives priority to patient autonomy, the concept of autonomy is 
insufficiently elaborated on. Criteria for the legal concept of “free 
will” require further explanation. Particularly, input from neuro-
biology, psychiatry and philosophy is needed. It is important to 
note that certain psychiatric diagnoses do not exclude freedom 
of will. Tebartz-van-Elst (75) showed the extent to which free 
will depends on certain mental functions and those that can be 
compromised by brain diseases.
We are convinced that individual court rulings would have 
come to a different conclusion in light of the mild encephalitis 
hypothesis of schizophrenia, assuming successful treatment of 
schizophrenia with anti-inflammatory drugs in a relevant sub-
group of patients.
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First, the Court extensively cited the adverse side effects of 
antipsychotic drugs. In contrast, current anti-inflammatory 
drugs such as aspirin and NAC are considered harmless; thus, 
making a ruling in favor of compulsory treatment more plausible.
Second, the Court’s decision was likely influenced by the fact 
that antipsychotics are merely a symptomatic, rather than a cura-
tive treatment for schizophrenia.
Third, the Court argued with the potential of antipsychotic 
medication to change the personality. Although it remained 
inconclusive with regard to the question whether schizophrenia 
is a psychosocial disorder or a genetically determined condition, 
as the disease was considered deeply ingrained to an individual’s 
personality. If the Court adopted the understanding of schizo-
phrenia as an acquired neurological condition, caused or trig-
gered by viruses, parasites, tumors or autoimmune processes, it 
would not condemn curative drugs. Rather, these drugs would 
have to be considered personality-restoring drugs. Particularly, the 
involvement of the parasitic protozoan T. gondii in schizophrenia 
might be a convincing argument for the judges, as its survival 
strategy can be explained by the manipulation hypothesis (38): 
T. gondii is transmitted from intermediate hosts such as mice 
and rats to its definitive hosts, namely cats, by predation. Hence, 
Toxoplasma relies on cats to eat infected rodents. For facilitating 
the transmission from the intermediate to the definite host, the 
parasite manipulates the rodents in several ways: reaction times 
become prolonged, and the rodents specifically lose their fear 
to cat odor; this peculiarity is called the fatal attraction phe-
nomenon. The same mechanism is probable in our next of kin: 
Toxoplasma-infected chimpanzees lose the fear to leopard urine 
(76). Toxoplasmosis can also cause similar behavioral changes in 
humans: it increases reaction times, resulting in higher probabil-
ity of traffic and work accidents; additionally, infected men rated 
the smell of cat urine as relatively more pleasant (38). The suicide 
rate of infected mothers is twice that of non-infected mothers 
(77). According to the manipulation hypothesis, these changes 
could result from the fact that our distant ancestors were also 
part of the leopards’ prey. In this context, schizophrenia cannot 
be seen as belonging to the core of the personality.
We expect that the threshold for allowing compulsory treat-
ment would decrease, if legal theorists and high judges accepted 
the mild encephalitis hypothesis of schizophrenia and if anti-
inflammatory drugs were more effective and had lesser adverse 
effects compared to antipsychotic medications.
However, we expect that the number of compulsory treat-
ment would be reduced significantly in the long run: if patients 
made the experience that physicians could effectively help them 
overcome their suffering in the psychotic phases without experi-
encing the adverse effects of antipsychotics, many would be more 
compliant with long-term treatment (if necessary). Furthermore, 
they might sign psychiatric advance directives (Ulysses contracts) 
for allowing drug treatment in case of another psychotic episode, 
even against the psychotic will (78). Finally, the better medical 
treatments can cure the disease, the lesser compulsory treatments 
would be necessary at all.
We recommend the following: the will of an acutely psychotic 
individual most likely differs significantly from his or her free 
will. In a psychotic state, reality perception is largely disturbed; 
the affect is changed; anxiety and panic dominate, such that the 
power of judgment is corrupted. Particularly, thought intrusions 
corrupt the individual’s free will. The affected person is not 
autonomous, and therefore lacks the capacity to give informed 
consent. Consequently, a proxy has to decide—but according to 
the affected individual’s will: first, according to his or her for-
merly declared will (ideally in an advance directive), second, to 
his or her assumed will, and third (in case that the latter two are 
unknown), in his or her best interest.
As we have argued elsewhere (79), respect for autonomy is also 
a positive duty. If a person’s capability for autonomy is corrupted 
by a disorder, respect for the person’s autonomy means primarily 
to restore her capability for autonomy. If restoration of the capa-
bility for autonomy is possible with antipsychotics and/or anti-
inflammatory medication, then it is a moral obligation to treat 
the person with these drugs. Once the capability for autonomy 
is restored, the patient can decide autonomously about his or her 
further treatment. However, if the patient has ruled out any of 
these treatments in an advance directive written in a state of legal 
competence, then this decision has to be respected, as well.
social inclusion
Until the 1970s, people with severe mental illness such as schizo-
phrenia were treated in psychiatric hospitals in great numbers. 
Due to their often chronic conditions and missing treatment 
options, they spent most of their lives in sanitariums or asylums 
(67). With the deinstitutionalization process, the responsibil-
ity of care for people with chronic mental illness shifted from 
hospital- to community-based health services. However, the 
chronic and severe course of schizophrenia often leads to mental 
and medical disability, unemployment, homelessness and even 
incarceration (4). Throughout Europe, less than 20% of people 
with schizophrenia are employed, and in the USA, people with 
severe mental illness are three times more likely to be found in 
the criminal justice system than in hospitals (4).
If new, more effective treatments were developed on ground 
of the mild encephalitis hypothesis, many patients with schizo-
phrenia of the mild encephalitis type could shift from being 
chronically ill and mentally disabled to being temporarily ill 
and treatable patients. Presumably, early interventions targeting 
underlying pathologies could prevent a chronic course of disease 
and cognitive impairment, enabling successful reintegration and 
participation in the community. However, it remains an open 
question as to how many patients could actually profit from these 
new therapeutic strategies.
Economically, employment of patients in remission can reduce 
indirect health costs, since the patient’s productivity is no longer 
lost and family members can partly pursue their professions (80). 
Employment improves the patient’s compliance and reduces 
hospital re-admission rates, which plays an important role in the 
patient’s quality of life (80).
stigmatization
Psychiatric disorders are severely stigmatized in both lay and 
professional settings (67, 81). Stigmatization means that people 
are classified and stereotyped due to a negatively connoted 
attribute. It is often associated with segregation, loss of social 
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status, discrimination in important contexts, and devaluation in 
a social hierarchy (82). Stigmatized individuals often develop self-
stigmatization and withdraw from society. Stigmatization often 
includes the families of stigmatized persons (courtesy stigma) 
(83).
The question, whether biological explanations for psychiatric 
disorders reduce or increase stigma, has been discussed contro-
versially for several decades.
The pessimistic fraction suspects that biologizing psychiatric 
disorders, particularly “genetic determinism,” intensifies discrimi-
nation and stigmatization, because it increases feelings of fear and 
unfamiliarity (84). Since it assumes an inborn predisposition for 
deviant behavior, it strengthens the assumption that the disease 
is unchangeable, persistent, and hereditable (85).
The optimistic fraction is convinced that biological explana-
tions reduce blame against persons with mental disorders, since it 
assumes that the main reason for stigmatization is the attribution 
of responsibility for the onset and/or maintenance of the deviant 
behavior. If a mental disorder is biologically caused, then the per-
son is not responsible for the onset nor the offset or the resulting 
behavior of the disorder (85).
Empirical research on stigmatization has shown that biologi-
cal explanations particularly increase stigmatization of diseases 
which are associated with perceived dangerousness and unpre-
dictability (81). Furthermore, poor treatment success increases 
stigmatization. Hence, biological explanations might reduce 
stigmatization as soon as successful treatment options are avail-
able (86).
Schizophrenia is associated with (1) perceived high danger-
ousness and unpredictability, (2) high psychosocial disability 
and exclusion, and (3) poor treatment success. However, onset 
and offset responsibility is low. Indeed, it has been shown that 
stigmatization of people with schizophrenia increases due to 
biological explanations (86, 87).
The mild encephalitis hypothesis will probably affect stig-
matization of schizophrenia in several ways: it does not support 
genetic determinism, but instead the concept of genetic vulner-
ability. Therefore, we expect that it will decrease stigmatization 
in comparison to mainly genetic explanations, but increase it 
compared to social explanations of schizophrenia.
With the mild encephalitis hypothesis, we do not expect a 
change concerning the attribution of onset responsibility. We 
expect a de-stigmatizing effect insofar as it offers some hope for 
better treatment strategies. Additionally, the patients’ compliance 
might improve due to less adverse effects of effective drugs, thus, 
in the long-term, relapse rates might be reduced and cognitive 
functioning improved. This could decrease the perceived dan-
gerousness and unpredictability of patients and improve their 
social inclusion. Furthermore, we expect reduced stigmatization 
of genetic relatives, if the influence of genes is seen not as a deter-
mination, but merely as a vulnerability factor.
Finally, we expect a major de-stigmatizing effect as soon as 
a multi-disciplinary approach in the treatment of schizophrenia 
is adopted, integrating psychiatry, neurology, and somatic 
disciplines.
The story of the popular German polar bear, Knut, might also 
contribute to destigmatization of schizophrenia because some 
empathy might be transferred from the bear to people suffering 
from psychosis.
In summary, we expect the mild encephalitis hypothesis to 
decrease stigmatization of patients with schizophrenia, provided 
effective drug therapies are developed based on biological find-
ings. Novel therapies based on anti-inflammatory substances 
might help not all, but a significant number of patients with 
schizophrenia of the mild encephalitis type.
ConCLUsion
We cannot predict the further scientific development in psy-
chiatry. Rather, we investigated the consequences of the mild 
encephalitis hypothesis of schizophrenia for the scientific com-
munity, and evaluated these consequences ethically. Most of these 
consequences are favorable from an ethical point of view.
Effective treatments of schizophrenia are urgently needed in 
order to reduce the burden for the patients, their relatives and 
society in general. For the development of effective treatment 
strategies, biological research on the etiology of schizophrenia 
is paramount. Research on both old and new drugs for treat-
ing mild encephalitis should be funded by public authorities. 
Increasing evidence supports the mild encephalitis hypothesis. 
Therefore, from both a scientific and an ethical point of view, 
further research on the role of inflammation in the etiology of 
schizophrenia and other psychiatric and neurological diseases is 
essential. Knowledge about the biological underpinnings of psy-
chiatric disorders should be transferred into clinical research and 
clinical practice. Biological tests, particularly paired serum-CSF 
analyses, should become standard investigations for all psychotic 
patients in order to identify the appropriate treatment for the 
individual patient.
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